Clinical trials: Frontotemporal Degeneration
Frontotemporal Lobar Degeneration
Multidisciplinary and Personalized Care of Behavioral Disorders in Frontotemporal Lobar Degeneration.
Fronto-Temporal Lobar Degeneration (FTLD) refers to 3 categories of neurodegenerative diseases generally occurring between 55 and 65 years: Fronto-Temporal Dementia(FTD), Primary Progressive Aphasia (PPA), Semantic Dementia (SD).
- Trial name
- DLFT (NCT03606798)
- Testing
- 3 Home visits made by a psychologist
- Where
- France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Alzheimer Disease, Alzheimer Dementia
Multimodal Ocular Imaging in Neurodegeneration
Alzheimer's disease (AD) and frontotemporal dementia (FTD) are two of the most common types of age-related neurodegenerative disorders.
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
- Trial name
- NCT03699644
- Testing
- Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Cognitively Normal Older Adults, Hypertension
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau…
- Conditions
- Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
- Trial name
- IPAT (NCT05331144)
- Testing
- Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Rong Zhang
Healthy Volunteer, Alzheimer Disease
Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]PI-2620, a tau targeted positron emission computed tomography radioligand, in individuals with tauopathies and healthy volunteers (HV).
- Conditions
- Healthy Volunteer, Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease
- Trial name
- NCT03510572
- Testing
- [18F]PI-2620
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Primary Progressive Aphasia
Language in Primary Progressive Aphasia
The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.
- Trial name
- NCT00537004
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Northwestern University
Frontotemporal Dementia
Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled Trial
Frontotemporal dementia (FTD) is a devastating neurodegenerative disorder. It is the second most frequent cause of presenile neurodegenerative dementia in those less than 65 years of age.
- Trial name
- PEA-FTD (NCT04489017)
- Testing
- PEA-LUT
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Frontotemporal Lobar Degeneration, Alzheimer Disease
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
The investigators will compare [18F]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched…
- Conditions
- Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
- Trial name
- NCT05456503
- Testing
- [18F]-PI-2620
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Frontotemporal Dementia
Flortaucipir PET Imaging in Subjects With FTD
This study is designed to assess the usefulness of flortaucipir in Positron Emission Tomography (PET) imaging for subjects diagnosed with Frontotemporal Dementia (FTD).
- Trial name
- NCT03040713
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Avid Radiopharmaceuticals
Rare Diseases
European Registry on Rare Neurological Diseases
The recent implementation of European Reference Networks for Rare Diseases (ERNs) is an unprecedented move to improve the care of patients suffering from rare health disorders by transnational collaboration.
- Trial name
- ERN-RND reg (NCT04319796)
- Testing
- Data set as defined by the ERN Research Workgroup of the European Commission
- Volunteers
- 5,000 people
- Sponsor
- University Hospital Tuebingen
Alzheimer's Disease, Mild Cognitive Impairment
A Composite MR Neuroimaging Marker for Alzheimer's Disease
The purpose of this study is to use a functional MRI (fMRI) index to compare the brain activity of healthy volunteers to that of people with mild cognitive impairment (MCI) and Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia
- Trial name
- NCT01615666
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Primary Progressive Aphasia, Frontotemporal Dementia
Long-term Effect of TMS in Primary Progressive Aphasia
There are very few treatments for neurodegenerative disorders, and the efficacy of these treatments is generally modest. Recent studies have shown a short-term positive effect of non-invasive neuromodulation techniques such as…
- Conditions
- Primary Progressive Aphasia, Frontotemporal Dementia, Alzheimer Disease
- Trial name
- RECONNECT (NCT05842473)
- Testing
- Transcranial Magnetic Stimulation (active), Language therapy
- Where
- Spain
- Volunteers
- 63 people
- Sponsor
- Hospital San Carlos, Madrid
Frontotemporal Degeneration, Progressive Supranuclear Palsy
Cognitive Impairement In Frontotemporal Dementia
This is an observational study that aims to better understand the genetic causes of frontotemporal degeneration (FTD), Multiple Systems Atrophy (MSA), and Progressive Supranuclear Palsy (PSP).
- Conditions
- Frontotemporal Degeneration, Progressive Supranuclear Palsy, Multiple System Atrophy
- Trial name
- NCT03452956
- Testing
- None-Observation Only
- Where
- United States
- Volunteers
- 997 people
- Sponsor
- University of Pennsylvania
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) is a rare clinical entity, in which both disorders are variably associated in the same patient or within the family.
- Trial name
- NCT00159198
- Where
- 15 sites in France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
This is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented…
- Trial name
- NCT05683860
- Testing
- WVE-004 10 mg Q12W
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Wave Life Sciences USA, Inc.
Alzheimer Disease
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
The recent development of a PET tracer,[18F]MK-6240(an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.
- Trial name
- MKADAD (NCT04104659)
- Testing
- MK 6240
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS
This observational study will use new smartwatch technology to continuously and remotely monitor the health of ALS patients and healthy controls over time. This information will be used to develop digital biomarkers for ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Muscular Atrophy, Progressive, Frontotemporal Dementia
- Trial name
- NCT05830214
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alberta
Alzheimer Disease, Frontotemporal Dementia
Proteinopathies Expression in Skin of Neurodegenerative Disorders
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 [TDP43]) in skin biopsies of…
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism
- Trial name
- NCT06528964
- Testing
- Immunohistochemistry and immunofluorescence
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Amyotrophic Lateral Sclerosis, Alzheimer's Disease
Advances in Telephone-based Cognitive Screening Procedures
1. Background Cognitive screening procedures via performance-based tests represent an essential, albeit preliminary, element within the diagnostic and interventional process as addressed to patients with chronic neurological…
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Degeneration
- Trial name
- TBCS (NCT06337578)
- Testing
- Telephone-based neuropsychological assessment - ALS, Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD, Telephone-based and in-person cognitive screening - NIs
- Where
- Italy
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
ALS (Amyotrophic Lateral Sclerosis), FTD
Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
Diagnosis of ALS/FTD disease spectrum is challenging because it largely relies on clinical symptoms. Identifying novel biomarkers is essential for a paradigm shift towards a more precise biological-based diagnosis.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), FTD, Neuropathic, Psychiatric Disorders
- Trial name
- SPECTRALS (NCT06856850)
- Where
- 4 sites in Italy
- Volunteers
- 230 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health